Madrigal’s therapy to treat MASH in adults gets EU’s initial nod
HQ Team June 22, 2025: Madrigal Pharmaceuticals EU Limited’s therapy to treat adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) got a conditional marketing.